Clinical trial · Observational
Weight Loss Management in Endometrial Cancer Survivors
Enacting Active Survivorship: Implementation of Weight Management Strategies in Endometrial Cancer Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to understand how oncologists can engage a multidisciplinary team to help endometrial cancer survivors with obesity to engage in a weight management program and potentially start a weight loss medication. Obesity often impacts the future health and longevity of early-stage endometrial cancer survivors more than their cancer diagnosis. Patients will be referred to the KUMC OB/Gyn weight management clinic to discuss weight management options. * If patients decide to use medications for weight loss, then the study will collect data from their chart that is recorded as part of routine monitoring for patients on weight loss medications. * If patients decide not to use any medications, the study will monitor physical exam and lab data collected as part of their routine medical care. The study will also try to understand reasons why patients did or did not start using a weight loss medication.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early Stage Endometrial Cancer | — | UNRESOLVED | — |
| Endometrial Cancer Survivors | — | UNRESOLVED | — |
| Weight Management | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Weight loss without pharmacotherapy | Behavioral | — | UNRESOLVED |
| Weight loss with pharmacotherapy | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Endometrial cancer survivors with weight management
- description
- Survivors of low-risk early-stage endometrial cancer up to 36 months post primary treatment with body mass index (BMI) ≥30 kg/m2
- interventionNames
- Behavioral: Weight loss with pharmacotherapy
- Behavioral: Weight loss without pharmacotherapy
Primary outcomes (1)
- measure
- Percentage of participants referred to weight loss clinic who are able to start weight management medications
- timeFrame
- 12 months
- description
- We will track the number of participants who do and do not start medication. Patients will be offered GLP-1 agonist, naltrexone/bupropion, orlistat, or phentermine/topiramate based discussion with weight management specialist.
Secondary outcomes (3)
- measure
- Change in insulin resistance over 12 months using HgA1c as a surrogate marker in participants on weight loss medications
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥18 years old * ECOG 0-2 * BMI ≥ 30kg/m2 * Completed surgical staging with no evidence of residual disease * Endometrioid endometrial adenocarcinoma, p53 wild type * Stage 1 * Undergoing active surveillance +/- brachytherapy Exclusion Criteria: * Unable to participate in behavior weight loss * Stroke, heart attack, end stage liver disease, or end stage kidney disease during the last 6 months. * Currently on a GLP-1 agonist * Currently on insulin
References
Publications (19)
- BACKGROUNDKlair N, Patel U, Saxena A, Patel D, Ayesha IE, Monson NR, Ramphall S. What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue. Cureus. 2023 Sep 29;15(9):e46197. doi: 10.7759/cureus.46197. eCollection 2023 Sep. PMID 37905277
- BACKGROUNDTondt, J., et al., Obesity Algorithm eBook, presented by the Obesity Medicine Association. 2023.
- BACKGROUNDEisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, de Luca M, Faria SL, Goodpaster KPS, Haddad A, Himpens JM, Kow L, Kurian M, Loi K, Mahawar K, Nimeri A, O'Kane M, Papasavas PK, Ponce J, Pratt JSA, Rogers AM, Steele KE, Suter M, Kothari SN. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg. 2023 Jan;33(1):3-14. doi: 10.1007/s11695-022-06332-1. PMID 36336720
- BACKGROUNDLonneman DJ Jr, Rey JA, McKee BD. Phentermine/Topiramate extended-release capsules (qsymia) for weight loss. P T. 2013 Aug;38(8):446-52. PMID 24222976
- BACKGROUNDJain SS, Ramanand SJ, Ramanand JB, Akat PB, Patwardhan MH, Joshi SR. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab. 2011 Apr;15(2):99-104. doi: 10.4103/2230-8210.81938. PMID 21731866
- BACKGROUNDKulak-Bejda A, Bejda G, Waszkiewicz N. Safety and efficacy of naltrexone for weight loss in adult patients - a systematic review. Arch Med Sci. 2020 Sep 10;17(4):940-953. doi: 10.5114/aoms.2020.96908. eCollection 2021. PMID 34336024
- BACKGROUNDUssher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023 Jul;20(7):463-474. doi: 10.1038/s41569-023-00849-3. Epub 2023 Mar 28.